Pharma – Talk Bio

pharma M&A 2025; biotech acquisitions; patent cliff; pharma patent expirations; Novo Nordisk Akero deal; Johnson & Johnson Intra-Cellular acquisition; Merck Verona Pharma deal; Sanofi Blueprint Medicines acquisition; FGF21 MASH deals; 2025 healthcare deals

Insilico Medicine and TaiGen sign exclusive licensing deal for AI-designed PHD inhibitor ISM4808 to treat anemia in chronic kidney disease

4 weeks ago talkbio0Tagged AI-driven, Anemia, CDE, China, Chronic Kidney Diseases, Clearance, clinical-stage biotech, Drug Discovery, Generative AI, Indonesian language, Insilico Medicine, ISM4808, License Agreement, Oral cavity, Ph.D., Pharma, PHD inhibitor, TaiGen Biotechnology

Insilico Medicine; TaiGen Biotechnology; license agreement; ISM4808; PHD inhibitor; anemia of Chronic Kidney Disease; CKD anemia; AI-driven drug discovery; Pharma.AI; Greater China rights; oral PHD inhibitor; IND clearance; China CDE; generative AI; clinical-stage biotech

Strategic solutions for cost, time and quality challenges in drug development – recent developments

1 month ago talkbio0Tagged Acceleration, Candidiasis, Chronic Mucocutaneous, CDMO/CRO, Clinical Development, cost-reduction, Drug Development, Efficiency, Optimization, Pharma, quality management, Study models, supply chain risk, TimeLine Fluoride Releasing Resin

drug development; cost reduction; timeline acceleration; quality management; integrated CDMO/CRO models; AI in pharma; CMC optimization; clinical development efficiency; supply chain risk; biotech strategy

Alkermes Ups Bid for Avadel Amid Lundbeck’s Competing Offer in Narcolepsy Drug Takeover Battle

2 months ago talkbio0Tagged Acquisition, Alkermes, Avadel Pharmaceuticals, bidding war, contingent value right, LUMRYZ, Lundbeck, M&A, Narcolepsy, Pharma, Primary Hypersomnia

Alkermes; Avadel Pharmaceuticals; Lundbeck; bidding war; Lumryz; narcolepsy; acquisition; contingent value right; pharma M&A; idiopathic hypersomnia

Eli Lilly Signs Up to $2.6 Billion Deal with South Korean Biotech for RNA Medicine Delivery

2 months ago talkbio0Tagged cardiometabolic, Deal Value, eli lilly, LEAD platform, Metabolic Diseases, News [Publication Type], Pharma, RNAi medicines, SanegeneBio, South Korean biotech, strategic partnership

Eli Lilly; SanegeneBio; South Korean biotech; RNAi medicines; metabolic diseases; LEAD platform; strategic partnership; cardiometabolic; deal value; pharma news